FMP
Inhibrx Biosciences, Inc.
INBX
NASDAQ
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
14.1 USD
-0.05 (-0.355%)
INBX Financial Statements
Year
2023
2022
2021
2020
Total Revenue
1.8M
2.18M
7.13M
12.81M
Cost of Revenue
1.19M
2.85M
2.69M
73.5M
Gross Profit
609k
-668k
4.44M
-60.69M
Operating Expenses
219.83M
131.29M
83.69M
80.25M
Research and Development
190.65M
110.19M
71.44M
73.5M
Selling, General & Administrative Expenses
29.38M
21.12M
12.36M
6.84M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
29.38M
21.12M
12.36M
6.84M
Other Expenses
0
-14k
-106k
-80k
Operating Income
-219.22M
-129.12M
-76.56M
-67.44M
Total Other Income/Expenses Net
-20.5M
-29.9M
-5.2M
-8.19M
Income Before Tax
-239.72M
-145.22M
-81.77M
-75.63M
Income Tax
3k
3k
2k
3k
Net Income
-241.36M
-145.23M
-81.77M
-75.64M
Basic EPS
-5.12
-3.62
-2.15
-2.99
EPS Diluted
-5.12
-3.62
-2.15
-2.99
Basic Average Shares
47.13M
40.11M
38.01M
25.26M
Diluted Average Shares
47.13M
40.11M
38.01M
25.26M
EBITDA
-206.69M
-125.82M
-76.56M
-67.44M
Retained Earning Schedule
Year
2023
2022
2021
2020
Retained Earnings (Previous Year)
-372.37M
-227.15M
-145.38M
-69.25M
Net Income
-241.36M
-145.23M
-81.77M
-75.64M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-613.73M
-372.37M
-227.15M
-145.38M
Other Distributions
-241.36M
-145.23M
-81.77M
-76.12M
PPE Schedule
Year
2023
2022
2021
2020
Gross PPE
9.37M
7.22M
9.49M
11.32M
Annual Depreciation
1.19M
1.23M
2.69M
2.39M
Capital Expenditure
-4.59M
-686k
-864k
-1.36M
Net PPE
12.77M
6.68M
7.67M
10.29M
Intangible and Goodwill Schedule
Year
2023
2022
2021
2020
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
